Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1634
This examiner grants 30% of resolved cases
Katie Leigh Pennington is an examiner in Art Unit 1633 within Tech Center 1600. The examiner has a total of 64 resolved cases. The allowance rate for these cases is 29.7 percent. This indicates a challenging prosecution environment for applicants. The examiner's record provides a specific look at prosecution trends in this art unit.
Conducting an interview appears to be a highly effective tactic with this examiner. The interview lift is 60.0 percent, indicating a substantial increase in the probability of allowance when an interview is held compared to the baseline rate of 29.7 percent. For applications that reach allowance, the median time to allowance is 1514 days. This pendency indicates that successful cases may require a longer period of time to resolve.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17924539 | DISEASE CORRECTION BY DELIVERY OF AAV8 VECTORS EXPRESSING CODON OPTIMIZED NAGLU | Final Rejection | University of Florida Research Foundation, Incorporated |
| 17772266 | GENE THERAPY VECTORS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17357652 | CELL TRANSPLANTATION KIT, METHOD FOR PRODUCING SAC-SHAPED STRUCTURE, AND THERAPEUTIC AGENT FOR DIABETES | Non-Final OA | FUJIFILM Corporation |
| 18580524 | HUMAN IPSC-DERIVED MACROPHAGES FOR LIVER REPAIR AND REGENERATION | Non-Final OA | The Regents of the University of California |
| 17442471 | ENGINEERED MRNA SEQUENCES AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 17904736 | NOVEL CRISPR-CAS SYSTEMS FOR GENOME EDITING | Final Rejection | PIONEER HI-BRED INTERNATIONAL, INC. |
| 17801815 | NOVEL TYPE IV AND TYPE I CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17759539 | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS COMPRISING A V30M MUTATION AND METHODS OF USE | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17820232 | CELL-TO-CELL DELIVERY OF RNA CIRCUITS | Final Rejection | California Institute of Technology |
| 19005128 | PATHOGEN-RESISTANT ANIMALS HAVING MODIFIED CD163 GENES | Non-Final OA | The Curators of the University of Missouri |
| 17909187 | METHODS OF CONTROLLING BODYWEIGHT BY MODULATING PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE BETA ACTIVITY | Final Rejection | University of Cincinnati |
| 17090706 | N-Glycosylation | Non-Final OA | Danmarks Tekniske Universitet |
| 18569795 | CELL CULTURE METHODS | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 18597181 | SYSTEM COMPRISING CISPLATIN-RESISTANT XENOGRAFT FOR NASOPHARYNGEAL CARCINOMA AND METHODS THEREOF | Non-Final OA | THE UNIVERSITY OF HONG KONG |
| 17634794 | HOLLOW THREE-DIMENSIONAL UNIT MADE FROM RETINAL TISSUE AND USE THEREOF IN THE TREATMENT OF RETINOPATHIES | Non-Final OA | TREEFROG THERAPEUTICS |
| 17756456 | MESENCHYMAL STEM CELLS WITH ENHANCED THERAPEUTIC PROPERTIES | Non-Final OA | UNIVERSITÉ DE MONTPELLIER |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy